Galecto and PharmAkea merge to create strong clinical-stage company developing first-in-class therapeutics in fibrosis and cancer
Galecto, the leading developer of galectin modulators for the treatment of fibrotic diseases including idiopathic pulmonary fibrosis (IPF) and cancer, and PharmAkea, Inc., a privately held San Diego-based pharmaceutical company developing novel small molecules against protein targets involved in fibroproliferative disease, today announced the two companies will merge.
Preclinical and clinical evidence for antifibrotic activity of Galecto’s lead compound, GB0139 (formerly TD139), contained in an abstract for the Experimental Biology 2020 conference
The poster presentation, available online as the conference was canceled due to COVID-19, described results from preclinical studies investigating galectin-3 in vitro and in vivo in naïve and bleomycin‐treated mice.
Galecto, PharmAkea Merger Creates Single Company with Strong Fibrotic Disease, Cancer Pipelines
Galecto Biotech and PharmAkea, two clinical-stage pharmaceutical companies with robust pipelines in fibrotic diseases and cancer, have merged into a single company.
Galecto to merge with onetime Celgene partner PharmAkea
Galecto is set to merge with PharmAkea. The deal will see Denmark’s Galecto incorporate in the U.S. and add a clinical-phase treatment for idiopathic pulmonary fibrosis (IPF) to its pipeline.
Galecto raises €79M to run late-phase IPF trial
Galecto Biotech has raised €79 million ($90 million) to take its treatment for idiopathic pulmonary fibrosis (IPF) into a phase 2/3 trial.
CFO-karrusel: To danske biotekfirmaer får nye finanschefer
To danske biotekselskaber får nye mænd til at styre finanserne. Den ene er samtidigt finansdirektør for et tredje dansk selskab med rødder i Novozymes.
Video: BIO-Europe® 2018_ Galecto Biotech’s CMO discusses the company’s recent EUR 79m Series C financing
Richard Marshall, chief medical officer at Galecto Biotech, talks to Scrip managing editor Joe Shorthouse about how a recent financing will allow the galectin modulator company to quickly push forward its product for idiopathic pulmonary fibrosis. He also discusses the company's work in the oral and ocular therapeutic areas.
